Application for CT-P55 Marketing Approval in Canada
Covers All Original Indications

Celltrion has applied for marketing approval of CT-P55, a biosimilar of Cosentyx (ingredient name: secukinumab), an autoimmune disease treatment, in Canada, marking the company's entry into the North American market.


Celltrion company logo image. Celltrion

Celltrion company logo image. Celltrion

View original image

On June 1, Celltrion announced that it had submitted an application to Health Canada for the approval of CT-P55. The application covers all indications for which Cosentyx is approved in Canada, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis.


This application is based on the results of a clinical trial conducted in 172 healthy adults. CT-P55 demonstrated pharmacokinetic (PK) equivalence compared to the original drug and also proved similarity in terms of safety and immunogenicity.


Starting with approval in Canada, Celltrion plans to sequentially pursue approval procedures in major markets, including the United States, Europe, and Korea.


CT-P55 is an interleukin (IL)-17A inhibitor and is expected to expand Celltrion's portfolio of autoimmune disease treatments. The company has built a product lineup that spans TNF-α inhibitors and interleukin inhibitors through products such as Remsima, Remsima SC (marketed as Zymfentra in the United States), Yuflyma, Stekimma, and Aptozyma.


The market potential is significant. Last year, the original drug Cosentyx recorded global sales of approximately USD 6.668 billion (about KRW 10 trillion).



Celltrion aims to use Canada, where biosimilar adoption policies are well established, as a bridgehead for entering the North American market. The company plans to expand its current portfolio of 11 biosimilar products to 18 by 2030. In the autoimmune disease field, biosimilars such as Ocrevus (CT-P53) and Taltz (CT-P52) are under development, while in oncology, biosimilars of Keytruda (CT-P51) and Darzalex (CT-P44) are also being developed.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing